Hostname: page-component-5c6d5d7d68-txr5j Total loading time: 0 Render date: 2024-08-13T12:20:12.095Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment of early resistant schizophrenia: a case report

Published online by Cambridge University Press:  19 July 2023

S. Benhammou ,
M. Raissouni  and
H. Kisra
S. Benhammou*
Affiliation:
Hospital Arrazi of sale, rabat, Morocco
M. Raissouni
Affiliation:
Hospital Arrazi of sale, rabat, Morocco
H. Kisra
Affiliation:
Hospital Arrazi of sale, rabat, Morocco
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Early-onset schizophrenia begins before the age of 18. Drug treatments are mainly based on antipsychotics, preferably atypical antipsychotics, which have fewer side effects compared to first generation antipsychotics.

Resistant schizophrenia is defined as an inadequate response to two different antipsychotic treatments for a sufficient duration and dosage. Clozapine is the only drug treatment currently approved for patients with resistant schizophrenia, for which the risk of aganulocytosis must be monitored.

In order to derive a clear benefit, different scientific organizations, recommend the use of Clozapine as early as possible, and they state that there is little evidence to support the use of very high doses of antipsychotics.

Objectives

We seek to determine the effectiveness of clozapine treatment in the management of early schizophrenia resistant to more than two antipsychotic treatments.

Methods

Description of a case of early resistant schizophrenia , in a 16-year-old girl, put on clozapine in comparison with the data of the literature.

Discussion: through articles published on google scholar, pubmed, and science direct

Results

Treatment with clozapine, showed efficacy in the case of early schizophrenia resistant to several lines of antipsychotics, including disappearance of auditory and visual hallucinations and delusions.

Conclusions

The efficacy of clozapine treatment in early resistant schizophrenia raises the question of its use in first line from the beginning of the schizophrenic disease, however its side effects and its difficulty of follow-up raise questions in relation to its use.

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S746
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.